Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly bladder radiation shows promise for patients unable to have standard treatment

NCT ID NCT01810757

Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a weekly, higher-dose radiation schedule (hypofractionated radiotherapy) for people with muscle-invasive bladder cancer who cannot have standard daily radiation or surgery. It included 65 participants and compared standard radiation planning with a newer 'adaptive' technique that adjusts the radiation field each session based on the bladder's changing shape. The goal was to see if this approach is safe and effective at controlling the tumor while reducing side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

65 people

The number who actually took part.

Started

Apr 2014

Finished

Apr 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Age ≥18 years * Histologically confirmed invasive bladder carcinoma (T2-T4a N0 M0; any histological sub-type) * Unsuitable for radical cystectomy or daily fractionated radiotherapy for any reason (including performance status, co-morbidity, patient refusal) * Expected survival \>6 months * WHO performance status 0-3 * Willing to undergo post treatment cystoscopy Exclusion Criteria: * Nodal or metastatic disease * Concurrent malignancy * Previous pelvic radiotherapy * Urinary catheter in-situ * Any other contra-indication to radiotherapy (e.g. inflammatory bowel disease) * Unable to attend for post treatment follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer

Contacts and locations

Locations

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral, United Kingdom

  • Guy's & St Thomas's Hospital

    London, United Kingdom

  • Ipswich Hospital

    Ipswich, United Kingdom

  • Norfolk & Norwich University Hospitals NHS Foundation Trust

    Norwich, United Kingdom

  • Queens Hospital

    Romford, United Kingdom

  • Royal Marsden NHSFT

    London, United Kingdom

  • Royal Preston Hospital

    Preston, United Kingdom

  • St James's University Hospital

    Leeds, United Kingdom

  • University College London

    London, United Kingdom

  • Velindre Cancer Centre

    Cardiff, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.